Here's a story about what happens when a small biotech company gets a nod from the biggest regulator in the business. Shares of NRx Pharmaceuticals Inc. (NRXP) are having a very good Monday, jumping more than 11% after the company announced the U.S. Food and Drug Administration has signaled a path forward for its experimental depression drug.

The drug in question is NRX-100, which is essentially a very specific, preservative-free version of intravenous ketamine. You might know ketamine as a dissociative anesthetic—it's used in surgery and pain management, and increasingly, it's being explored for mental health treatment. It has some hallucinogenic effects, which is part of why it's interesting for conditions like depression that haven't responded to other treatments.

The big news here isn't just that the FDA is willing to look at the application. It's how they're willing to look at it. The agency told NRx it would review a New Drug Application (NDA) based on "substantial evidence of effectiveness" from existing trials. Crucially, they didn't ask for any new clinical trials. That's a huge deal. Developing a new drug is incredibly expensive and time-consuming, and skipping the "go run another massive study" step can shave years off the timeline and save millions of dollars.

Instead, NRx plans to submit existing patient-level data for the FDA to review. The company says it intends to file its full NDA by June 2026. So, we're not talking about approval tomorrow, but we are talking about a potentially expedited review process for a drug that addresses a massive unmet need.

And what is that need? The data on NRX-100 is pretty compelling, especially when it comes to the most severe symptom of depression: suicidal thoughts. In trials, the drug showed "dramatic superiority" to placebo treatments. It also showed it was non-inferior to electroconvulsive therapy (ECT), which is currently the only FDA-approved treatment specifically for suicidal ideation.

Here's the kicker: ECT, often called electroshock therapy, works, but it comes with a significant side effect. About 30% of patients experience memory loss. Ketamine, in these trials, did not. So you have a treatment that appears to be as effective as the current gold standard for stopping suicidal thoughts, but without one of its most devastating side effects. That's a powerful value proposition.

The market potential is staggering. Over 16 million Americans experience a major depressive episode each year, and of those, about 3.6 million contemplate suicide. A safe and effective treatment for that specific, acute crisis could be a blockbuster.

Now, let's talk about the stock, because that's why we're all here. The share price reaction makes sense given the news. But where does it go from here? The technical picture is a bit of a mixed bag.

On the positive side, the stock is trading well above its short-term averages—14.8% above its 20-day simple moving average and 3.3% above its 50-day. That suggests some recent bullish momentum. It's also up about 1.86% over the past year and is trading closer to its 52-week high than its low, which is relatively stable for a volatile biotech name.

On the other hand, it's still below its longer-term averages—8.2% below the 100-day and a hefty 20.7% below the 200-day. That suggests the longer-term trend hasn't fully turned positive yet. The Relative Strength Index (RSI) is sitting at a neutral 48.03, meaning the stock isn't overbought or oversold. The MACD indicator, however, is showing a slight bullish crossover, which can be a positive signal for traders.

The combination paints a picture of a stock that got good news and popped, but one where the longer-term trend is still playing catch-up. Traders are watching key resistance at $2.50 and support at $1.75.

What do the professionals think? Analysts covering the stock are overwhelmingly bullish. The consensus rating is a Buy, and recent actions have been aggressive:

• D. Boral Capital maintains a Buy rating with a $34.00 target (March 9).
• HC Wainwright & Co. raised its price target to $45.00 from a previous level, also with a Buy rating (March 3).
• BTIG maintains a Buy rating with a $25.00 target (February 18).

Those targets, ranging from $25 to $45, are miles above the stock's current price around $2.07. That disconnect tells you everything about the high-risk, high-reward nature of biotech investing. The analysts are betting heavily on the drug's eventual approval and commercial success.

For ETF investors looking for exposure, NRx is a notable holding in the AdvisorShares Psychedelics ETF (PSIL), with a 4.81% weight. It's a pure-play on the emerging psychedelic and novel mental health treatment space.

So, to sum up: A small company got a potentially game-changing regulatory communication. Its drug works for a devastating condition where good options are scarce. The stock reacted immediately. Now, everyone gets to wait and see if the company can execute on the path the FDA has outlined, file a compelling application by 2026, and ultimately bring a new tool to doctors and patients who desperately need it. The market, and the analysts, are betting they can.